Released Mar 6, 2023, after the close
10-K filed Mar 6, 2023, 65 days after period end · 0000950170-23-006242
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$122.23M$122.23M derived−2.3% vs Q4 2021+7.2% vs Q3 2022
Net Income-$7.06M-$7.06M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$89,176,000−2.9%
Operating Incomederived-$11,044,000N/M
Operating Cash Flowderived$2,348,000−80.1%
Free Cash Flowderived-$2,857,000N/M
Margins · derived
Gross margin73.0%−0.5 pt vs Q4 2021
Operating margin-9.0%−1.6 pt vs Q4 2021
Net margin-5.8%+20.5 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $122.23M | $125.06M | $117.62M | $121.49M |
| Net Income | -$7.06M | -$32.81M | -$9.38M | $11.69M |
| EPS Diluted | — | — | — | $0.60 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR